vs
Side-by-side financial comparison of KB HOME (KBH) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.7B, roughly 1.4× KB HOME). Zoetis runs the higher net margin — 25.3% vs 6.0%, a 19.3% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -15.3%). Zoetis produced more free cash flow last quarter ($732.0M vs $290.1M). Over the past eight quarters, KB HOME's revenue compounded faster (7.4% CAGR vs 4.4%).
KB Home is an American homebuilding company founded in 1957 as Kaufman & Broad in Detroit, Michigan. It was the first company to be traded on the New York Stock Exchange as a home builder. Its headquarters are in Los Angeles, California.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
KBH vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $2.4B |
| Net Profit | $101.5M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | 6.0% | 25.3% |
| Revenue YoY | -15.3% | 3.0% |
| Net Profit YoY | -46.7% | 3.8% |
| EPS (diluted) | $1.55 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.7B | $2.4B | ||
| Q3 25 | $1.6B | $2.4B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $2.0B | $2.3B | ||
| Q3 24 | $1.8B | $2.4B | ||
| Q2 24 | $1.7B | $2.4B | ||
| Q1 24 | $1.5B | $2.2B |
| Q4 25 | $101.5M | $603.0M | ||
| Q3 25 | $109.8M | $721.0M | ||
| Q2 25 | $107.9M | $718.0M | ||
| Q1 25 | $109.6M | $631.0M | ||
| Q4 24 | $190.6M | $581.0M | ||
| Q3 24 | $157.3M | $682.0M | ||
| Q2 24 | $168.4M | $624.0M | ||
| Q1 24 | $138.7M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | — | 31.9% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 33.0% | ||
| Q1 24 | — | 34.1% |
| Q4 25 | 6.0% | 25.3% | ||
| Q3 25 | 6.8% | 30.0% | ||
| Q2 25 | 7.1% | 29.2% | ||
| Q1 25 | 7.9% | 28.4% | ||
| Q4 24 | 9.5% | 25.1% | ||
| Q3 24 | 9.0% | 28.6% | ||
| Q2 24 | 9.9% | 26.4% | ||
| Q1 24 | 9.4% | 27.4% |
| Q4 25 | $1.55 | $1.37 | ||
| Q3 25 | $1.61 | $1.63 | ||
| Q2 25 | $1.50 | $1.61 | ||
| Q1 25 | $1.49 | $1.41 | ||
| Q4 24 | $2.50 | $1.29 | ||
| Q3 24 | $2.04 | $1.50 | ||
| Q2 24 | $2.15 | $1.37 | ||
| Q1 24 | $1.76 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.9B | $3.3B |
| Total Assets | $6.7B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $3.9B | $3.3B | ||
| Q3 25 | $3.9B | $5.4B | ||
| Q2 25 | $4.0B | $5.0B | ||
| Q1 25 | $4.1B | $4.7B | ||
| Q4 24 | $4.1B | $4.8B | ||
| Q3 24 | $4.0B | $5.2B | ||
| Q2 24 | $4.0B | $5.0B | ||
| Q1 24 | $3.9B | $5.1B |
| Q4 25 | $6.7B | $15.5B | ||
| Q3 25 | $7.0B | $15.2B | ||
| Q2 25 | $7.0B | $14.5B | ||
| Q1 25 | $7.0B | $14.1B | ||
| Q4 24 | $6.9B | $14.2B | ||
| Q3 24 | $6.8B | $14.4B | ||
| Q2 24 | $6.8B | $14.2B | ||
| Q1 24 | $6.7B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $303.8M | $893.0M |
| Free Cash FlowOCF − Capex | $290.1M | $732.0M |
| FCF MarginFCF / Revenue | 17.1% | 30.7% |
| Capex IntensityCapex / Revenue | 0.8% | 6.7% |
| Cash ConversionOCF / Net Profit | 2.99× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $287.3M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $303.8M | $893.0M | ||
| Q3 25 | $197.7M | $938.0M | ||
| Q2 25 | $168.4M | $486.0M | ||
| Q1 25 | $-334.3M | $587.0M | ||
| Q4 24 | $362.6M | $905.0M | ||
| Q3 24 | $-89.9M | $951.0M | ||
| Q2 24 | $61.5M | $502.0M | ||
| Q1 24 | $28.5M | $595.0M |
| Q4 25 | $290.1M | $732.0M | ||
| Q3 25 | $185.8M | $805.0M | ||
| Q2 25 | $156.9M | $308.0M | ||
| Q1 25 | $-345.5M | $438.0M | ||
| Q4 24 | $352.6M | $689.0M | ||
| Q3 24 | $-99.4M | $784.0M | ||
| Q2 24 | $51.2M | $370.0M | ||
| Q1 24 | $19.1M | $455.0M |
| Q4 25 | 17.1% | 30.7% | ||
| Q3 25 | 11.5% | 33.5% | ||
| Q2 25 | 10.3% | 12.5% | ||
| Q1 25 | -24.8% | 19.7% | ||
| Q4 24 | 17.6% | 29.7% | ||
| Q3 24 | -5.7% | 32.8% | ||
| Q2 24 | 3.0% | 15.7% | ||
| Q1 24 | 1.3% | 20.8% |
| Q4 25 | 0.8% | 6.7% | ||
| Q3 25 | 0.7% | 5.5% | ||
| Q2 25 | 0.8% | 7.2% | ||
| Q1 25 | 0.8% | 6.7% | ||
| Q4 24 | 0.5% | 9.3% | ||
| Q3 24 | 0.5% | 7.0% | ||
| Q2 24 | 0.6% | 5.6% | ||
| Q1 24 | 0.6% | 6.4% |
| Q4 25 | 2.99× | 1.48× | ||
| Q3 25 | 1.80× | 1.30× | ||
| Q2 25 | 1.56× | 0.68× | ||
| Q1 25 | -3.05× | 0.93× | ||
| Q4 24 | 1.90× | 1.56× | ||
| Q3 24 | -0.57× | 1.39× | ||
| Q2 24 | 0.37× | 0.80× | ||
| Q1 24 | 0.21× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KBH
| Home Building | $1.7B | 99% |
| Financial Service | $8.7M | 1% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
